JP2023548046A - 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 - Google Patents

抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 Download PDF

Info

Publication number
JP2023548046A
JP2023548046A JP2023524629A JP2023524629A JP2023548046A JP 2023548046 A JP2023548046 A JP 2023548046A JP 2023524629 A JP2023524629 A JP 2023524629A JP 2023524629 A JP2023524629 A JP 2023524629A JP 2023548046 A JP2023548046 A JP 2023548046A
Authority
JP
Japan
Prior art keywords
antibody
seq
dose
patient
patients weighing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548046A5 (https=
Inventor
クリスタ ケー． ジョンソン，
ポール ピー． タンブリーニ，
ダグラス エル． シェリダン，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2023548046A publication Critical patent/JP2023548046A/ja
Publication of JP2023548046A5 publication Critical patent/JP2023548046A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47—Scattering, i.e. diffuse reflection
    • G01N2021/4704—Angular selective
    • G01N2021/4711—Multiangle measurement
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2023524629A 2020-10-23 2021-10-22 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法 Pending JP2023548046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105018P 2020-10-23 2020-10-23
US63/105,018 2020-10-23
PCT/US2021/056153 WO2022087339A1 (en) 2020-10-23 2021-10-22 Methods of treating patients having complement disorders using anti-c5 antibodies

Publications (2)

Publication Number Publication Date
JP2023548046A true JP2023548046A (ja) 2023-11-15
JP2023548046A5 JP2023548046A5 (https=) 2024-10-29

Family

ID=78695818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524629A Pending JP2023548046A (ja) 2020-10-23 2021-10-22 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法

Country Status (5)

Country Link
US (1) US20240018220A1 (https=)
EP (1) EP4232473A1 (https=)
JP (1) JP2023548046A (https=)
CA (1) CA3196434A1 (https=)
WO (1) WO2022087339A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
CN118512588A (zh) 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
KR102365871B1 (ko) * 2017-01-31 2022-02-21 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
CN118512588A (zh) * 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
CA3274059A1 (en) * 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. CONE ET AL.: "Formation of multivalent complexes in the presence of more than one conventional antibody to complem", BRITISH JOURNAL OF HAEMATOLOGY, vol. 189, no. 1, JPN6025051644, 27 April 2020 (2020-04-27), pages 145 - 146, ISSN: 0005753909 *

Also Published As

Publication number Publication date
US20240018220A1 (en) 2024-01-18
EP4232473A1 (en) 2023-08-30
CA3196434A1 (en) 2022-04-28
WO2022087339A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
KR102763158B1 (ko) 최적화된 항tl1a 항체
WO2019062832A1 (zh) Tigit抗体、其抗原结合片段及医药用途
CN111138540A (zh) 治疗自身免疫疾病的结合fcrn的抗体
WO2018177393A1 (zh) B7-h3抗体、其抗原结合片段及其医药用途
WO2019154315A1 (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
JP2019534010A (ja) ピログルタメートアミロイド−βに対する抗体及びその使用
CN113166241B (zh) 人类znt8抗体
EA023406B1 (ru) Антитела к гепцидину и варианты их применения
JP2023548046A (ja) 抗ｃ５抗体を使用する、補体障害を有する患者の処置方法
CN107428822A (zh) 抗甲状腺素运载蛋白抗体
BR112020019647A2 (pt) Anticorpo anti-cd27, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
WO2021160116A1 (zh) 抗FcRn抗体、其抗原结合片段及其医药用途
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
WO2021110095A1 (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP2023548046A5 (https=)
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN108178798B (zh) pH工程化的NGF抗体及其医药用途
WO2018228406A1 (zh) Pcsk9抗体、其抗原结合片段及其医药用途
JP2022528953A (ja) 抗タウｃ３抗体及びその使用
JP2016510870A (ja) 補体因子ｈ関連タンパク質１検出のための剤、キットおよび方法
WO2022078490A1 (zh) 抗erbb3抗体或其抗原结合片段及其医药用途
WO2023025249A1 (zh) 一种含融合蛋白的药物组合物
CN118317976A (zh) 针对FcγRIIA的结合分子及其应用
CN115109157A (zh) 抗体或其抗原结合片段，其制备方法及医药用途
WO2023198138A1 (zh) 抗体或其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260313